| Company Name: |
MQ (shanghai) Pharmaceuticals Co., Ltd.
|
| Tel: |
13761635123 |
| Email: |
1014988033@qq.com |
| Products Intro: |
Product Name:(2-Hydroxy-4-morpholinophenyl)(phenyl)methanone
CAS:404009-46-7
Purity:＞95% Package:1G，5G
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:AMA-37;AMA37
CAS:404009-46-7
Purity:98% Package:10 mg
|
|
| | 1-(2-HYDROXY-4-MORPHOLIN-4-YL-PHENYL)-PHENYL-METHANONE Basic information |
| | 1-(2-HYDROXY-4-MORPHOLIN-4-YL-PHENYL)-PHENYL-METHANONE Chemical Properties |
| storage temp. | Store at -20°C | | form | Solid | | color | White to yellow |
| | 1-(2-HYDROXY-4-MORPHOLIN-4-YL-PHENYL)-PHENYL-METHANONE Usage And Synthesis |
| Definition | ChEBI: [2-hydroxy-4-(4-morpholinyl)phenyl]-phenylmethanone is a member of benzophenones. | | Biological Activity | AMA-37, an Arylmorpholine analog, is ATP-competitive DNA-PK inhibitor, with IC50 values of 0.27 μM (DNA-PK), 32 μM (p110α), 3.7 μM (p110β), and 22 μM (p110γ), respectively[1][2].
AMA-37 inhbits PI3K poorly[2].AMA-37 (20 μM) reduces the ability of UCN-01, isogranulatimide, and debromohymenialdesine, but not caffeine, to overcome G2 arrest (Ρ < 0.05)[3].Inhibition of DNA-PK with AMA37 leads to radiosensitization[3]. | | References | [1]. Zachary A Knight, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006 May 19;125(4):733-47. [2]. Zachary A Knight, et al. Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg Med Chem. 2004 Sep 1;12(17):4749-59. [3]. Christopher M Sturgeon, et al. Effect of combined DNA repair inhibition and G2 checkpoint inhibition on cell cycle progression after DNA damage. Mol Cancer Ther. 2006 Apr;5(4):885-92. |
| | 1-(2-HYDROXY-4-MORPHOLIN-4-YL-PHENYL)-PHENYL-METHANONE Preparation Products And Raw materials |
|